Shockwave Reducer Demonstrates Sustained Three-Year Improvement in CCS Class and Quality of Life in Chronic Angina Patients, Johnson & Johnson Reports at ESC 2024

Sep 05, 2024 22:15 CST Updated 22:15

Johnson & Johnson

Healthcare Product Manufacturers, Health Service Providers

Johnson & Johnson Announces Innovative Angina Treatment at ESC 2024 ConferenceShockwave ReducerClinical research data (REDUCER-I). The study showsShockwave ReducerAfter TreatmentContinuous safety and effectiveness, andCCS and QoLThe positive improvement lasted for 3 years.

REDUCER-I is a post-marketing, multi-center, observational study aimed at collecting data from a large "real-world" population of 400 patients.Shockwave ReducerThe long-term outcomes. From 2016 to 2023, 400 patients were enrolled (78.0% (312/400) male, 46.5% (185/398) with diabetes, 73.6% (293/398) post-revascularization, 71.6% (235/369) with CCS III/IV).

Specific Research Data

At 12 months post-operation,展现出Continuous Safety and Efficacy ，CCS and QoL showed significant improvement sustained over 3 years.。

At 12 months postoperatively, after treatmentThe number of patients visiting the emergency department significantly decreased, from a baseline of 33.1% to 13.3%.

Angina PectorisAngina pectoris is a clinical syndrome characterized by paroxysmal chest pain or chest discomfort primarily caused by insufficient blood supply from the coronary arteries, leading to a sudden but temporary lack of blood and oxygen in the myocardium. Angina pectoris reflects the heart's ischemic pain sensed on the body surface. The pain is typically paroxysmal and compressive in the anterior chest, often accompanied by other symptoms. It is mainly located behind the sternum and can radiate to the precordial area and the left upper limb. Episodes commonly occur during physical exertion or emotional excitement, each lasting 3 to 5 minutes. Attacks may happen once every few days or several times a day, disappearing after rest or using nitrate medications.

The conventional treatment for angina involves medication, such as beta-blockers or calcium channel blockers, which can prevent angina attacks. Additionally, for patients experiencing sudden chest pain, sublingual nitroglycerin is used to alleviate symptoms. In severe cases, treatments may include widening blood vessels or utilizing bypass circulation to increase blood supply to the heart.

The number of patients with angina is very large, with 6 million angina patients in the United States and up to 16 million angina patients in China. Moreover, the global number of angina patients is still growing rapidly. Currently, the conventional treatment for angina involves medication, such as beta-blockers or calcium channel blockers, which can prevent angina attacks.

Despite optimal medical therapy, millions of people worldwide with angina pectorisPatients with angina cannot derive any benefit from drug therapy.And Johnson & Johnson'sShockwave ReducerExpected to change the current state of angina treatment, clinical research shows its potential in treating angina.

Neovasc Reducer

Neovasc ReducerIt is a small, balloon-expandable dumbbell-shaped stent that can narrow the coronary sinus, thereby allowing blood...Redistributed to ischemic myocardium.

Neovasc ReducerIncluding the delivery system and stent.

Neovasc ReducerThe stent is made from a stainless steel tube through laser cutting. The stent is designed in a dumbbell shape, narrow in the middle (3mm in diameter) and wide at both ends (13mm).

The shape of the distal balloon of the delivery system is consistent with the stent, and there are three radiopaque rings on the balloon, located at both ends and the middle of the balloon respectively.

Neovasc Reducer Demonstration

Shockwave Medical

ShockWave MedicalAs part of Johnson & Johnson's medical device division, it aims to transform the treatment of calcified cardiovascular diseases.ShockWave MedicalThe goal is to establish a new standard for medical device treatment of cardiovascular calcification diseases through its differentiated and proprietary localized delivery of ultrasound for the treatment of calcified plaques, which they callIntravascular Lithotripsy（“IVL”）。